Congress.wiki Alpha
AboutHow Congress WorksQuizCongress WrappedSupport UsRoadmapHealthPrivacy PolicyTerms of Service
WhiteHouse.wikiSCOTUS.wiki

Get a weekly summary of what Congress did, delivered every Monday.

This is not an official government website.

Copyright © 2026 PLEJ LC. All rights reserved.

Map
Live
Schedule
Daily Record
Special Rules
Subpoenas
Foreign Influence
Agencies
Regulations
Office Spending
US Code
Open search

Federal Regulations

How Congress's laws become real-world rules. Browse regulatory dockets from Regulations.gov — tracking rulemaking activity, public comment periods, and the agencies turning legislation into policy.

Dockets
3,873
Regulations.gov

Showing 30 of 3,873 dockets

Rulemaking
EPA
Open for Comments

EPA-HQ-OLEM-2025-3456

Paper Manifest Sunset Rule; Modification of the Hazardous Waste Manifest Regulations

3 docs16 comments
Comments due May 5, 2026
Rulemaking
EPA
Open for Comments

EPA-HQ-OLEM-2025-1707

Clean Water Act Hazardous Substance Facility Response Plans; Amendment Reconsideration

4 docs29 comments
Comments due May 20, 2026
Rulemaking
EPA

EPA-HQ-OLEM-2021-0585

Clean Water Act Hazardous Substance Worst Case Discharge Planning Regulations

181 docs29 comments
Rulemaking
EPA
Open for Comments

EPA-HQ-OLEM-2025-1609

Protecting Public Health and Unleashing American Energy by Facilitating Scrap Tire Pile Cleanups

21 docs8 comments
Comments due May 23, 2026
Rulemaking
EPA
Open for Comments

EPA-HQ-OAR-2024-0503

Protection of Stratospheric Ozone: Listing of Substitutes under the Significant New Alternatives Policy Program in Refrigeration and Air Conditioning and Fire Suppression

90 docs53 comments
Comments due May 7, 2026
Rulemaking
EPA
Open for Comments

EPA-HQ-OLEM-2025-0313

Risk Management Programs under the Clean Air Act; Common Sense Approach to Chemical Accident Prevention

78 docs69 comments
Comments due May 12, 2026
Nonrulemaking
NRCS
Open for Comments

NRCS-2025-0236

Information Collection Request; Advancing Markets for Producers

1 doc3 comments
Comments due Apr 14, 2026
Nonrulemaking
FDA
Open for Comments

FDA-2025-P-6350

Requests that the FDA initiate notice-and-comment rulemaking to amend 21 CFR § 1271.90 to extend the existing regulatory exception for surplus cryopreserved embryos to surplus cryopreserved oocytes originally recovered for a woman’s own reproductive use

2 docs1 comment
Nonrulemaking
FDA
Open for Comments

FDA-2025-P-6223

Requests that the FDA rescind 21 CFR 801.109 in its entirety or substantially narrow the scope of 21 CFR 801.109 by amending it to limit prescription-only status to those devices that present a meaningful potential for harmful misuse or overdose in the absence of practitioner supervision.

2 docs1 comment
Nonrulemaking
FDA
Open for Comments

FDA-2025-P-4153

Requests that the FDA require revisions to the labeling for all over-the-counter acetaminophen-containing drug products marketed under the Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use monograph (OTC Monograph M013): (i) a revision to the “Warnings” subsection, currently found at M013.50(c)(1)(iii) in the Labeling section.

5 docs307 comments
Nonrulemaking
FDA

FDA-2026-H-1232

DAB Civil Money Penalty; CRV Management LLC, d/b/a Amigo Tropical Drive Thru 2; CLOSED 04/09/2026

1 docNo comments
Nonrulemaking
FDA
Open for Comments

FDA-2025-P-3287

Request that the FDA remove the Mifepristone REMS Program, including but not limited to the Prescriber Certification, Pharmacy Certification, and Patient Agreement form for the reasons set forth below and in the Mifepristone Multistate Citizen Petition (FDA-2025-P-1576)

57 docs16 comments
Rulemaking
OPM

OPM-2025-0273

Performance Appraisal for General Schedule, Prevailing Rate, and Certain Other Employees

2 docs601 comments
Nonrulemaking
FRA

FRA-2026-0463

Brandon Sherman, ALTON & SOUTHERN RWY

6 docsNo comments
Nonrulemaking
FRA
Open for Comments

FRA-2026-0067

Liam Bartholomay- Engineer Certification

2 docsNo comments
Nonrulemaking
FDA
Open for Comments

FDA-2025-P-3071

Requests that the FDA Limit the Exposure of Refined Carbohydrates used in Industrial Processing in order to Prevent Obesity, Diabetes, and Cardiovascular Disease in Children and Adults

3 docs489 comments
Rulemaking
FMCSA
Open for Comments

FMCSA-2025-0655

Fees for the Unified Carrier Registration Plan and Agreement (2026)

1 doc7 comments
Comments due May 8, 2026
Nonrulemaking
FAA
Open for Comments

FAA-2026-3731

Air Strike Drone Services LLC - Exemption/Rulemaking

2 docsNo comments
Nonrulemaking
FDA
Open for Comments

FDA-2025-P-2162

Requests that absent new peer-reviewed studies or otherwise robust scientific or clinical evidence warranting such action, FDA take no action that would reduce patient access to mifepristone and/or increase the burdens associated with prescribing or dispensing mifepristone.

12 docs119 comments
Nonrulemaking
FDA

FDA-2026-H-3700

DAB Civil Money Penalty; Shahs Da LLC d/b/a Amoco / To Go

1 docNo comments
Nonrulemaking
FDA
Open for Comments

FDA-2025-P-1576

Request that the FDA remove the Mifepristone REMS Program, including but not limited to the Prescriber Certification, Pharmacy Certification, and Patient Agreement form

23 docs154 comments
Rulemaking
OPM

OPM-2025-0239

Reduction in Force (RIF) Appeals

2 docs1.3K comments
Nonrulemaking
FDA
Open for Comments

FDA-2025-P-1242

Request that the FDA immediately suspend the approval of mifepristone (brand name: Mifeprex) for use in chemical abortions until a comprehensive safety review can be conducted under current real-world prescribing conditions.

4 docs7 comments
Nonrulemaking
FDA
Open for Comments

FDA-2025-P-1025

Request that the FDA take the following four actions: 1) Mandate Warning Labels: Require infant formula products to carry prominent warnings informing consumers that introducing formula can reduce breastmilk production due to decreased infant suckling, which is essential for maintaining lactation 2) Regulate Marketing Claims: Prohibit marketing language that suggests formula is designed to

3 docs19 comments
Nonrulemaking
FDA
Open for Comments

FDA-2025-P-0876

Request that the FDA amend the labeling regulations for infant formula, including specialty formulas, to require the following warnings on all packaging and marketing materials: “Formula feeding increases the risk of infections-such as ear infections, diarrhea, lower respiratory infections

3 docs15 comments
Nonrulemaking
OSHA
Open for Comments

OSHA-2010-0041

Logging Operations (29 CFR 1910.266). OMB Control Number 1218-0198

15 docs1 comment
Comments due May 27, 2026
Rulemaking
CMS
Open for Comments

CMS-2026-1123

FY 2027 Inpatient Psychiatric Facilities Prospective Payment System – Rate Update. CMS-1847-P

2 docs23 comments
Comments due Jun 2, 2026
Nonrulemaking
FDA
Open for Comments

FDA-2026-P-3844

Requests that the FDA declare that the drug products Desmopressin Acetate Tablets, 0.05 mg and 0.15 mg, are suitable for consideration in an Abbreviated New Drug Application.

5 docsNo comments
Nonrulemaking
FDA

FDA-2026-H-3269

DAB Civil Money Penalty; 418 West Dickson Street, LLC d/b/a Always 420 King Tobacco Smoke Shop

1 docNo comments
Rulemaking
CMS
Open for Comments

CMS-2026-1156

FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements. CMS-1851-P

2 docs6 comments
Comments due Jun 2, 2026
  • Previous
  • Page 13 of 130
  • Next